Fold change | |||
---|---|---|---|
Gene symbol | UC active involved versus control | UC remission versus control | UC active involved versus UC remission |
Pattern 1 | |||
COL1A2 | 7.0** | 1.1 | 6.3** |
CXCL1 | 21.1** | 1.9 | 11.1** |
CXCL3 | 11.5** | 1.9 | 6.0* |
IGHG1/G4/@/G3/V4–31/M | 59.5** | 1.3 | 44.1* |
IL8 | 29.6** | 1.6 | 18.1* |
NFKBIZ | 2.9** | 1.1 | 2.8** |
REG1A | 1363.4** | 3.4 | 403.4** |
VCAN | 3.9** | −1.1 | 4.4* |
WNT5A | 5.1** | −1.1 | 5.7** |
Pattern 2 | |||
AQP8 | −59.8** | −9.4** | −6.3* |
CHI3L1 | 626.0** | 12.3** | 50.9** |
LILRB2 | 7.3** | 1.8* | 4.0* |
MMP1 | 111.8** | 13.8** | 8.1* |
MMP3 | 354.8** | 22.6** | 15.7* |
TGFBI | 5.9** | 2.0** | 2.9* |
TIMP1 | 10.9** | 4.0** | 2.8* |
Pattern 3 | |||
ABCG2 | −8.3** | −4.7* | −1.8 |
ACOX1 | −2.2** | −1.9** | −1.1 |
ACSL4 | 6.1** | 2.4** | 2.6 |
ADH6 | −2.3* | −1.7* | −1.4 |
AQP3 | 3.1** | 4.0** | −1.3 |
CXCL5 | 44.7** | 3.9* | 11.5 |
DEFB1 | −3.3** | −1.9* | −1.7 |
GJA1 | 4.2** | 2.1** | 2 |
IL1B | 18.7** | 2.6* | 7.1 |
IL1RN | 12.7** | 7.9** | 1.6 |
IL6R | −1.7* | −1.4* | −1.2 |
ME1 | 5.7** | 6.6** | −1.2 |
MMP10 | 48.8** | 10.4** | 4.7 |
REG4 | 25.1** | 22.7** | 1.1 |
RUNDC3B | −3.1* | −2.3* | −1.3 |
S100P | 8.6** | 13.0** | −1.5 |
SERPINB5 | 10.0** | 15.2** | −1.5 |
SLC16A1 | −3.5* | −2.9** | −1.2 |
SMAD7 | −1.9** | −1.5* | −1.3 |
TFF1 | 9.7** | 6.0** | 1.6 |
TFPI2 | 13.3** | 6.3** | 2.1 |
TRIM29 | 7.9** | 9.8** | −1.3 |
*p<0.05.
**p<0.005.
Relative change (fold change) in gene expression determined by real-time RT-PCR in non-IBD controls, involved areas of active UC patients (UC active involved), and involved areas of UC patients in endoscopic remission (UC remission). Based on their relative expression among groups, genes could be classified into three different patterns (described in figure 2). Significant adjusted p values from a Mann-Whitney-Wilcoxon test are shown as.
IBD, inflammatory bowel disease; RT-PCR, reverse transcriptase PCR; UC, ulcerative colitis.